uniQure (NASDAQ:QURE) has been assigned a $28.00 price objective by equities researchers at HC Wainwright in a research report issued on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 64.51% from the stock’s current price.

QURE has been the topic of several other reports. Zacks Investment Research cut shares of uniQure from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Evercore ISI initiated coverage on shares of uniQure in a research report on Tuesday, November 7th. They set an “outperform” rating and a $22.00 target price on the stock. ValuEngine cut shares of uniQure from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Oppenheimer restated a “hold” rating on shares of uniQure in a research report on Friday, November 24th. Finally, Leerink Swann upped their target price on shares of uniQure from $17.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.29.

uniQure (NASDAQ:QURE) traded up $2.02 on Thursday, hitting $17.02. 1,642,200 shares of the company’s stock traded hands, compared to its average volume of 310,974. uniQure has a twelve month low of $4.72 and a twelve month high of $21.35. The company has a quick ratio of 3.64, a current ratio of 3.64 and a debt-to-equity ratio of 0.73.

Institutional investors have recently bought and sold shares of the stock. Mangrove Partners purchased a new stake in uniQure in the 2nd quarter worth about $247,000. OxFORD Asset Management LLP purchased a new stake in uniQure in the 3rd quarter worth about $399,000. JPMorgan Chase & Co. raised its position in uniQure by 33.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after purchasing an additional 14,659 shares during the period. Renaissance Technologies LLC raised its position in uniQure by 48.8% in the 1st quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock worth $2,162,000 after purchasing an additional 122,700 shares during the period. Finally, Morgan Stanley raised its position in uniQure by 14.9% in the 1st quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock worth $3,271,000 after purchasing an additional 73,418 shares during the period. 24.87% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “HC Wainwright Analysts Give uniQure (QURE) a $28.00 Price Target” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/12/07/uniqure-qure-rating-reiterated-by-hc-wainwright.html.

About uniQure

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Analyst Recommendations for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.